To determine if the regorafenib and nivolumab combination (RegoNivo) improves overall
survival compared with current standard chemotherapy options in refractory AGOC.
Phase:
Phase 3
Details
Lead Sponsor:
Australasian Gastro-Intestinal Trials Group
Collaborators:
Academic and Community Cancer Research United Bayer Bristol-Myers Squibb Canadian Cancer Trials Group Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest Taiwanese Cooperative Oncology Group University of Sydney